{
    "title": "113_hr5124",
    "content": "SECTION 1. SHORT TITLE; TABLE OF CONTENTS.\n\n    (a) Short Title.--This Act may be cited as the ``Sickle Cell \nDisease Research, Surveillance, Prevention, and Treatment Act of \n2014''.\n    (b) Table of Contents.--The table of contents of this Act is as \nfollows:\n\nSec. 1. Short title; table of contents.\nSec. 2. Sickle cell disease research.\nSec. 3. Sickle cell disease surveillance.\nSec. 4. Sickle cell disease prevention and treatment.\nSec. 5. Collaboration with community-based entities.\nSec. 6. Authorization of appropriations.\n\nSEC. 2. SICKLE CELL DISEASE RESEARCH.\n\n    Part P of title III of the Public Health Service Act is amended by \ninserting after section 399V-5 (42 U.S.C. 280g-16) the following:\n\n``SEC. 399V-6. NATIONAL SICKLE CELL DISEASE RESEARCH, SURVEILLANCE, \n              PREVENTION, AND TREATMENT PROGRAM.\n\n    ``(a) Research.--The Secretary may conduct or support research to \nexpand the understanding of the cause of, and to find a cure for, \nsickle cell disease.''.\n\nSEC. 3. SICKLE CELL DISEASE SURVEILLANCE.\n\n    Section 399V-6 of the Public Health Service Act, as added by \nsection 2, is amended by adding at the end the following:\n    ``(b) Surveillance.--\n            ``(1) Grants.--The Secretary shall, for each fiscal year \n        for which appropriations are available to carry out this \n        subsection, make grants to not more than 20 States--\n                    ``(A) to conduct surveillance and maintain data on \n                the prevalence and distribution of sickle cell disease \n                and its associated health outcomes, complications, and \n                treatments;\n                    ``(B) to conduct public health initiatives with \n                respect to sickle cell disease, including--\n                            ``(i) increasing efforts to improve access \n                        to, and receipt of, high-quality sickle cell \n                        disease-related health care, including the use \n                        of proven treatments such as Hydroxyurea;\n                            ``(ii) working with partners to improve \n                        health outcomes of people with sickle cell \n                        disease over the lifespan by promoting \n                        guidelines for sickle cell disease screening, \n                        prevention, and treatment, including management \n                        of sickle cell disease complications;\n                            ``(iii) providing support to community-\n                        based organizations and State and local health \n                        departments in conducting sickle cell disease \n                        education and training activities for patients, \n                        communities, and health care providers; and\n                            ``(iv) supporting and training State health \n                        departments and regional laboratories in \n                        comprehensive testing to identify specific \n                        forms of sickle cell disease in people of all \n                        ages; and\n                    ``(C) to identify and evaluate promising strategies \n                for prevention and treatment of sickle cell disease \n                complications, including through--\n                            ``(i) improving estimates of the national \n                        incidence and prevalence of sickle cell \n                        disease, including estimates about the specific \n                        types of sickle cell disease;\n                            ``(ii) identifying health disparities \n                        related to sickle cell disease;\n                            ``(iii) assessing the utilization of \n                        therapies and strategies to prevent \n                        complications related to sickle cell disease; \n                        and\n                            ``(iv) evaluating the impact of genetic, \n                        environmental, behavioral, and other risk \n                        factors that may affect sickle cell disease \n                        health outcomes.\n            ``(2) Population included.--The Secretary shall, to the \n        extent practicable, award grants under this subsection to \n        States across the United States so as to include data on the \n        majority of the United States population with sickle cell \n        disease.\n            ``(3) Application.--To seek a grant under this subsection, \n        a State shall submit an application to the Secretary at such \n        time, in such manner, and containing such information as the \n        Secretary may require.\n            ``(4) Definitions.--In this subsection:\n                    ``(A) The term `Secretary' means the Secretary of \n                Health and Human Services, acting through the Director \n                of the National Center on Birth Defects and \n                Developmental Disabilities.\n                    ``(B) The term `State' includes the 50 States, the \n                District of Columbia, the Commonwealth of Puerto Rico, \n                the United States Virgin Islands, the Commonwealth of \n                the Northern Mariana Islands, American Samoa, Guam, the \n                Federated States of Micronesia, the Republic of the \n                Marshall Islands, and the Republic of Palau.''.\n\nSEC. 4. SICKLE CELL DISEASE PREVENTION AND TREATMENT.\n\n    (a) Reauthorization.--Section 712(c) of the American Jobs Creation \nAct of 2004 (Public Law 108-357; 42 U.S.C. 300b-1 note) is amended--\n            (1) by striking ``Sickle Cell Disease'' each place it \n        appears and inserting ``sickle cell disease'';\n            (2) in paragraph (1)(A), by striking ``grants to up to 40 \n        eligible entities for each fiscal year in which the program is \n        conducted under this section for the purpose of developing and \n        establishing systemic mechanisms to improve the prevention and \n        treatment of Sickle Cell Disease'' and inserting ``grants to up \n        to 25 eligible entities for each fiscal year in which the \n        program is conducted under this section for the purpose of \n        developing and establishing systemic mechanisms to improve the \n        prevention and treatment of sickle cell disease in populations \n        with a high density of sickle cell disease patients'';\n            (3) in paragraph (1)(B)--\n                    (A) by striking clause (ii) (relating to priority); \n                and\n                    (B) by striking ``Grant award requirements'' and \n                all that follows through ``The Administrator shall'' \n                and inserting ``Geographic diversity.--The \n                Administrator shall'';\n            (4) in paragraph (2), by adding the following new \n        subparagraph at the end:\n                    ``(E) To expand, coordinate, and implement \n                transition services for adolescents with sickle cell \n                disease making the transition to adult health care.''; \n                and\n            (5) by striking paragraph (6).\n    (b) Technical Changes.--\n            (1) Subsection (c) of section 712 of the American Jobs \n        Creation Act of 2004 (Public Law 108-357; 42 U.S.C. 300b-1 \n        note) is--\n                    (A) transferred to the Public Health Service Act \n                (42 U.S.C. 201 et seq.); and\n                    (B) inserted at the end of section 399V-6 of such \n                Act, as added and amended by sections 2 and 3 of this \n                Act.\n            (2) The table of contents in section 1(c) of the American \n        Jobs Creation Act of 2004 (Public Law 108-357) is amended by \n        striking the item relating to section 712.\n\nSEC. 5. COLLABORATION WITH COMMUNITY-BASED ENTITIES.\n\n    Section 399V-6 of the Public Health Service Act, as amended by \nsection 3, is further amended by adding at the end the following:\n    ``(c) Collaboration With Community-Based Entities.--To be eligible \nto receive a grant or other assistance under subsection (a), (b), or \n(c), an entity must have in effect a collaborative agreement with a \ncommunity-based organization with 5 or more years of experience in \nproviding services to sickle cell disease patients.''.\n\nSEC. 6. AUTHORIZATION OF APPROPRIATIONS.\n\n    Section 399V-6 of the Public Health Service Act, as amended by \nsection 5, is further amended by adding at the end the following:\n    ``(d) Authorization of Appropriations.--To carry out this section, \nthere are authorized to be appropriated $20,000,000 for each of fiscal \nyears 2015 through 2020.''."
}